Essex Investment Management Co. LLC lessened its stake in BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 12.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 305,446 shares of the company's stock after selling 42,315 shares during the quarter. Essex Investment Management Co. LLC owned about 1.62% of BrainsWay worth $2,880,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of BrainsWay by 316.3% in the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock valued at $136,000 after purchasing an additional 11,221 shares in the last quarter. Rhumbline Advisers increased its stake in shares of BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after buying an additional 2,144 shares during the period. Finally, ARK Investment Management LLC bought a new stake in shares of BrainsWay during the fourth quarter worth $1,656,000. 30.11% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of BrainsWay in a report on Wednesday.
View Our Latest Report on BWAY
BrainsWay Trading Down 0.9 %
Shares of BWAY traded down $0.09 on Thursday, reaching $10.21. 47,692 shares of the company's stock were exchanged, compared to its average volume of 74,404. The business has a 50 day moving average price of $10.24 and a two-hundred day moving average price of $9.59. BrainsWay Ltd. has a 12 month low of $4.61 and a 12 month high of $11.79. The stock has a market capitalization of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29.
BrainsWay Company Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
